Atglistatin
Atglistatin is an inhibitor of adipose triglyceride lipase (ATGL) that decreases fatty acid mobilization and prevents lipolysis. Atglistatin also prevents triglyceride accumulation after acute myocardial infarction, displaying cardioprotective benefit.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18842775
| Cas No. |
1469924-27-3 |
|---|---|
| Formula |
C17H21N3O |
| Formula Wt. |
283.38 |
| IUPAC Name |
3-[4-(Dimethylamino)-3-biphenylyl]-1,1-dimethylurea |
Zhang H, Sun T, Jiang X, et al. PEDF and PEDF-derived peptide 44mer stimulate cardiac triglyceride degradation via ATGL. J Transl Med. 2015 Feb 21;13:68. PMID: 25890298.
Cerk IK, Salzburger B, Boeszoermenyi A, et al. A peptide derived from G0/G1 switch gene 2 acts as noncompetitive inhibitor of adipose triglyceride lipase. J Biol Chem. 2014 Nov 21;289(47):32559-70. PMID: 25258314.
Mayer N, Schweiger M, Romauch M, et al. Development of small-molecule inhibitors targeting adipose triglyceride lipase. Nat Chem Biol. 2013 Dec;9(12):785-7. PMID: 24096302.
